Merck Adds To Diabetes Franchise With SmartCells Acquisition
This article was originally published in The Pink Sheet Daily
Executive SummaryMerck announced Dec.2 that it is acquiring privately-held SmartCells for the company's preclinical SmartInsulin diabetes program in a deal potentially worth as much as $500 million. The acquisition will help bolster sales of Merck's blockbuster diabetes drug Januvia.
You may also be interested in...
Novo Nordisk has bought UK-based start-up Ziylo in hopes of accelerating development of glucose-responsive insulins, but admits any such products are at least ten years away.
They’re not just for seed rounds anymore: in the life sciences, rich individuals are supplying more early stage capital than ever, occasionally well past the Series A stage, and some are banding together into groups that look increasingly like traditional venture capital. How far will this phenomenon fly?
The first tool that will be developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome.